Kidney Cancer News and Research

RSS

Kidney cancer is usually defined is a cancer that originates in the kidney. The two most common types of kidney cancer, reflecting their location within the kidney, are renal cell carcinoma (RCC) and urothelial cell carcinoma (UCC) of the renal pelvis.

Researchers discover genetic mechanism for resistance to immunotherapy drugs

An urgent question for cancer scientists is why immunotherapy achieves dramatic results in some cases but doesn't help most patients.

5 Jan 2018

New MRI technology can reduce need for tumor biopsies

The most common type of tumor found in the kidney is generally quite small (less than 1.5 in). These tumors are usually found by accident when CAT scans are performed for other reasons and the serendipitous finding poses a problem for doctors.

3 Jan 2018

Second edition of Open Accelerator program unveils winning Life Science start-ups

Zcube today announces the winners of the second edition of its Open Accelerator program aimed at Life Science start-ups and entirely supported by the Italian company: Zambon.

22 Dec 2017

Novel drug shows promise in treating metastatic kidney cancer

Metastatic kidney cancer remains largely incurable. Despite a dozen treatments and several immunotherapies, survival rates beyond 5 years remain around 10 percent.

21 Dec 2017

Researchers question exclusion of people with prior cancer history from clinical trials

A quarter of newly diagnosed cancer patients 65 or older are survivors who had a prior cancer – often preventing them from participating in clinical trials, researchers from UT Southwestern's Simmons Cancer Center have found.

22 Nov 2017

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy).

17 Nov 2017

Research identifies molecular mechanism that causes kidney cancer to resist drug treatment

New research from The University of Texas Health Science Center at San Antonio and U.S. Department of Veterans Affairs has identified the molecular mechanism that causes kidney cancer to resist drug treatment.

25 Oct 2017

Researchers provide evidence of increase in cancer decades after arsenic exposure ends

A new paper published in the Journal of the National Cancer Institute shows that arsenic in drinking water may have one of the longest dormancy periods of any carcinogen.

24 Oct 2017

New study describes unique role of androgens in kidney cancer

A new study is believed to be the first to describe the unique role of androgens in kidney cancer, and it suggests that a new approach to treatment, targeting the androgen receptor (AR), is worth further investigation.

13 Oct 2017

Combination immunotherapy shows better overall survival in kidney cancer patients

A combination immunotherapy treatment showed better overall survival in patients with previously untreated advanced or metastatic renal cell carcinoma than current therapy, according to results from a phase 3 clinical trial presented at the Presidential Symposium of the European Society for Medical Oncology's 2017 Congress in Spain.

13 Sep 2017

Multigene panel test could be useful to detect patients with hereditary kidney cancer syndrome

A multigene panel test could be a useful diagnostic tool to help clinicians identify patients with a hereditary kidney cancer syndrome, according to the results of a study published in Cancer.

13 Sep 2017

Penn researcher wins National Cancer Institute Outstanding Investigator Award

M. Celeste Simon, PhD, who studies cancer cell metabolism, tumor immunology, and the influence of oxygen availability and deprivation on tumor growth, has been given a National Cancer Institute Outstanding Investigator Award.

8 Sep 2017

Review of kidney cancer incidence in California signals end of a trend

A review of kidney cancer in California from 1988 through 2013 by the UC Davis Institute for Population Health Improvement has concluded that the high incidence of small tumors and early-stage disease observed in California from 1988 until about 2009 has declined and stabilized in recent years, signaling the end of a trend.

18 Aug 2017

Researchers identify new factors that may affect brain tumor cells' ability to resist treatment

The most aggressive variant of brain tumor - glioblastoma - has an average survival rate of 15 months. There is therefore an urgent need for new treatment strategies for this group of patients.

16 Aug 2017

Better analysis of kidney tumor samples

Every year, just over 1000 people are diagnosed with kidney cancer in Sweden. The three most common variants are clear cell, papillary and chromophobe renal cancer.

11 Aug 2017

Combination therapy shows efficacy, safety in treating metastatic renal cell cancer

A new cooperative research study including Norris Cotton Cancer Center's Lionel Lewis, MB BCh, MD, finds that nivolumab plus ipilimumab therapy demonstrated manageable safety, notable antitumor activity, and durable responses with promising long term overall survival in patients with metastatic renal cell cancer (mRCC).

26 Jul 2017

Diagnosing prostate cancer through a £225 urine test

This test, which we have branded SelectMDx for Prostate Cancer, came with the acquisition of a company in the Netherlands called NovioGendix. They developed a prototype assay, so they did most of the heavy lifting in terms of discovering the two specific biomarkers that are currently in the product. These biomarkers are tuned towards the detection of what I call clinically significant prostate cancer.

24 Jul 2017

Latinos left out of clinical trials … and possible cures

Two decades ago, Luis Antonio Cabrera received devastating news: He likely had only three months to live.

19 Jul 2017

Combination therapy may lead to new standard of care for kidney cancer patients

Combination therapy with two immunotherapy drugs produces an unprecedented doubling of response rates from 20 percent to 40 percent, new study shows.

6 Jul 2017

Experimental drug benefits some patients with advanced kidney cancer

Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.

24 Jun 2017